{"id":"aav2-hchm","safety":{"commonSideEffects":[{"rate":"null","effect":"Vision impairment"},{"rate":"null","effect":"Eye inflammation"}]},"_chembl":{"chemblId":"CHEMBL4594315","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AAV2-hCHM is a recombinant adeno-associated virus vector that carries a normal copy of the RPE65 gene to replace the faulty gene in patients with Leber congenital amaurosis.","oneSentence":"Gene therapy for Leber congenital amaurosis","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:51:21.966Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leber congenital amaurosis"}]},"trialDetails":[{"nctId":"NCT02341807","phase":"PHASE1, PHASE2","title":"Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations","status":"COMPLETED","sponsor":"Spark Therapeutics, Inc.","startDate":"2015-01-15","conditions":"Choroideremia, CHM (Choroideremia) Gene Mutations","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AAV2-hCHM","genericName":"AAV2-hCHM","companyName":"Spark Therapeutics, Inc.","companyId":"spark-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gene therapy for Leber congenital amaurosis Used for Leber congenital amaurosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}